NCT02621489View on ClinicalTrials.gov

Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

August 31, 2022

Study Completion Date

October 31, 2022

Conditions
AtherosclerosisDiabetesRestenosis
Interventions
DRUG

Bydureon

2 mg Once Weekly

DRUG

Humulin kwickpen

Humulin kwickpen 10U QD at bedtime

DRUG

Metformin

Metformin 1g BID

Trial Locations (1)

11883

Dept of clinical science and education Karolinska Institutet Södersjukhuset, Stockholm

All Listed Sponsors
lead

Karolinska Institutet

OTHER

NCT02621489 - Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects | Biotech Hunter | Biotech Hunter